The FDA has cleared the BridgeSource SmartRead system, a diagnostic tool designed to identify the brand and model of cardiac implants.
Refining Heart Transplant Prioritization
Researchers have proposed the U.S. Candidate Risk Score to better prioritize the sickest adult patients awaiting heart transplants. Registry data modeling suggests the score could reduce waitlist deaths without significantly increasing the geographic distance donor grafts must travel. In a related development for pediatric care, investigators described a new pediatric-specific rapid recovery method using extended ultra-oxygenated preservation techniques, according to the New England Journal of Medicine.
Addressing Environmental and Clinical Risks
European cardiovascular groups have released formal guidance for clinicians to advise patients on the specific cardiac risks posed by extreme heat. The guidance, published in the European Heart Journal, details how rising temperatures can exacerbate underlying heart conditions and provides strategies for patient protection.
Data Updates in Cardiomyopathy and Diagnostics
Cytokinetics reported new cardiopulmonary exercise testing data from the ACACIA-HCM trial, supporting the use of aficamten (Myqorzo) for patients with nonobstructive hypertrophic cardiomyopathy. In parallel, the JACC: Heart Failure journal reported that in the ATTRibute-CM study, early increases in serum transthyretin levels were linked to subsequent changes in NT-proBNP, creating a ratio that may predict long-term clinical outcomes.
Long-term Health Trends and Complications
Data from the National Health and Nutrition Examination Survey (1999–2023) indicates that LDL cholesterol levels have improved in younger populations without atherosclerotic cardiovascular disease, Circulation reported. However, a meta-analysis published in JAMA Cardiology found that intensive blood pressure lowering remains beneficial even for patients with chronic kidney disease. Separately, real-world data published in BMJ Medicine linked pregnancy complications to a higher long-term risk of developing cardiovascular disease, type 2 diabetes, and chronic kidney disease. Meanwhile, research highlighted by the American Heart Association indicates that popular artificial intelligence chatbots frequently provide incorrect information regarding whether specific blood pressure monitors are clinically validated.
Legal Disputes and Manufacturing Milestones
State Sen. James Tedisco has called on New York Gov. Kathy Hochul to intervene in a legal dispute between Ellis Medicine and St. Peter’s Healthcare. The litigation, centered on noncompete agreements, threatens to disrupt care for approximately 50,000 cardiology patients. In device manufacturing, Johnson & Johnson reported that its Shockwave peripheral intravascular lithotripsy therapy maintained safety and effectiveness at 24 months in the DISRUPT BTK II study. Elsewhere, the FDA maintains a clinical hold on the experimental schizophrenia drug evenamide due to concerns regarding potential fatal arrhythmias. Finally, a global observational study in the British Journal of Ophthalmology found that statin users may experience a protective effect against the progression of glaucoma requiring surgery.
Worth a look